Abstract
Background: There is no curative treatment for Alzheimer’s disease (AD). Ginseng is widely used in the treatment of AD in Asian countries. Objective: To evaluate the effectiveness and safety of ginseng for AD. Methods: We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results. Results: Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events. Conclusion: This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.
Keywords: Alzheimer’s disease, Ginseng, Ginsenoside, Meta-analysis, Randomized controlled trial, Systematic review.
Current Topics in Medicinal Chemistry
Title:Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Volume: 16 Issue: 5
Author(s): Yuyi Wang, Guoyan Yang, Juan Gong, Fang Lu, Qingchun Diao, Jin Sun, Kang Zhang, Jinzhou Tian and Jianping Liu
Affiliation:
Keywords: Alzheimer’s disease, Ginseng, Ginsenoside, Meta-analysis, Randomized controlled trial, Systematic review.
Abstract: Background: There is no curative treatment for Alzheimer’s disease (AD). Ginseng is widely used in the treatment of AD in Asian countries. Objective: To evaluate the effectiveness and safety of ginseng for AD. Methods: We searched seven main databases for randomized clinical trials (RCTs) on ginseng for AD from their inception to December 2014. The Cochrane risk of bias tool was used to assess the methodological quality. We used RevMan 5.2 to synthesize the results. Results: Four RCTs involving 259 participants were identified for this systematic review. The methodological quality of included studies was not promising. All comparisons were made between combined treatment (ginseng plus conventional treatment) versus conventional treatment. The results of meta-analyses and several individual studies showed that the effectiveness of combined treatment was inconsistent as measured by MMSE, ADAS-cog, ADAS-noncog, and CDR. No studies reported the outcomes of quality of life (QoL). The current data did not report serious adverse events. Conclusion: This review showed that the effects of ginseng on AD were still inconclusive. The main limitations of the available studies were small sample sizes, poor methodological qualities and no placebo controls. Larger, well-designed studies are needed to test the effect of ginseng on AD in the future.
Export Options
About this article
Cite this article as:
Wang Yuyi, Yang Guoyan, Gong Juan, Lu Fang, Diao Qingchun, Sun Jin, Zhang Kang, Tian Jinzhou and Liu Jianping, Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current Topics in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1568026615666150813143753
DOI https://dx.doi.org/10.2174/1568026615666150813143753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotransmitter Dysfunction and Neurotransmitter Replacement Therapy as Part of Frontotemporal Dementia Treatment
Current Psychiatry Reviews Non-Globular Structures of Tandem Repeats in Proteins
Protein & Peptide Letters Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Current Alzheimer Research Right Temporal Variant Frontotemporal Dementia Misdiagnosed as Schizophrenia
Current Psychiatry Research and Reviews A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Advanced Glycation End Products, Oxidative Stress and Metalloproteinases are altered in the Cerebral Microvasculature during Aging
Current Neurovascular Research Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Development of Novel Amyloid Imaging Agents Based Upon Thioflavin S
Current Alzheimer Research Antiphospholipid Syndrome: Characteristics and Obstetrical Management
Current Drug Targets Acetylcholine Receptors and Tau Phosphorylation
Current Molecular Medicine Recent Developments on the Studies of Human Memapsin 2 (β-Secretase)
Current Alzheimer Research Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review
Current Psychiatry Reviews Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology